Immunitybio Inc (IBRX)

$2.70 -0.09 (-3.23%)
Market Cap 2.44B
Revenue (ttm) 14.75M
Net Income (ttm) -413.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,803.80%
Debt to Equity Ratio 0.00
Volume 15,434,992
Avg Vol 9,443,528
Day's Range N/A - N/A
Shares Out 882.62M
Stochastic %K 25%
Beta 0.14
Analysts Strong Sell
Price Target $11.40

Company Profile

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead b...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 696 5235
Address:
3530 John Hopkins Court, San Diego, United States
Diosces
Diosces Jun. 27 at 10:07 PM
$IBRX Saddest POS ever invested in... or yeah + that other shitbag 'pharma' $ALT
1 · Reply
Cancercrusader
Cancercrusader Jun. 27 at 9:37 PM
$IBRX https://brownstone.org/articles/fda-exposed-hundreds-of-drugs-approved-without-proof-they-work/ The FDA and Big Pharma ladies and gentlemen, poisoning Americans since day one.
0 · Reply
BixbyKnolls
BixbyKnolls Jun. 27 at 9:33 PM
$IBRX Wow- Some more AH BLOCKs trades going off. Now around 15.4 million shares for today. Interesting.. any mews behind this?
1 · Reply
windswept
windswept Jun. 27 at 9:19 PM
$IBRX David Din
0 · Reply
Chuckwagon23
Chuckwagon23 Jun. 27 at 8:46 PM
$IBRX first time I read this I thought it said "retarded". Me thinking, this guy is spot on. Every morning here buddy.
0 · Reply
John_morris
John_morris Jun. 27 at 8:39 PM
$IBRX What's with that BIG VOLUME going into Close ? Anybody care to share their input.
1 · Reply
VerrrrrrrryInteresting
VerrrrrrrryInteresting Jun. 27 at 8:37 PM
$IBRX Just guessing but that's what swapping spit looks like when the HFs buy-sell from each other to avoid end of month margin calls/square up their books. Totally guessing but with market at ATHs and many high beta stocks popping the past few weeks they NEEDED this one to go/stay down. NO ONE else has an 8MM share block to sell for someone to buy. JMHO but I've seen this slimy game before with HFs, especially when other holdings are going against them. However, I HOPE it was a new buyer taking a stake for the beginning :)
0 · Reply
elitechrisvp
elitechrisvp Jun. 27 at 8:24 PM
$IBRX 😁👍
0 · Reply
Catredeye
Catredeye Jun. 27 at 8:21 PM
$IBRX My little 548 buy went through at 123-127 pm blocks of 100 and 148 for 2.74 then of course it dropped after that. Like always. No matter still waiting with my measly 9555 shares .
1 · Reply
CagedMoney
CagedMoney Jun. 27 at 8:17 PM
$IBRX Monday will be interesting
2 · Reply
Latest News on IBRX
ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

Jun 12, 2025, 9:09 AM EDT - 15 days ago

ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Jun 3, 2025, 8:45 AM EDT - 24 days ago

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

Jun 2, 2025, 9:00 AM EDT - 25 days ago

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

May 27, 2025, 8:00 AM EDT - 4 weeks ago

ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

May 12, 2025, 6:30 AM EDT - 6 weeks ago

ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

May 5, 2025, 5:05 PM EDT - 7 weeks ago

ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

May 5, 2025, 9:21 AM EDT - 7 weeks ago

ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

May 5, 2025, 6:30 AM EDT - 7 weeks ago

ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Apr 29, 2025, 12:50 PM EDT - 2 months ago

ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

Apr 28, 2025, 8:30 AM EDT - 2 months ago

Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

Apr 21, 2025, 4:21 PM EDT - 2 months ago

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Apr 15, 2025, 8:00 AM EDT - 2 months ago

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

Apr 8, 2025, 7:30 AM EDT - 2 months ago

ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

Apr 7, 2025, 5:00 AM EDT - 2 months ago

ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch

ImmunityBio: Taking Care Of Business

Apr 3, 2025, 5:54 PM EDT - 3 months ago

ImmunityBio: Taking Care Of Business

ImmunityBio to Host Investor Day

Mar 26, 2025, 6:00 AM EDT - 3 months ago

ImmunityBio to Host Investor Day

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

Mar 13, 2025, 9:00 AM EDT - 3 months ago

ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

Mar 7, 2025, 1:47 AM EST - 4 months ago

ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

Mar 3, 2025, 7:30 AM EST - 4 months ago

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

Feb 27, 2025, 7:10 PM EST - 4 months ago

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

Feb 19, 2025, 9:00 AM EST - 4 months ago

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Feb 13, 2025, 3:05 PM EST - 4 months ago

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Jan 29, 2025, 8:30 AM EST - 5 months ago

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Jan 27, 2025, 9:00 AM EST - 5 months ago

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

Jan 17, 2025, 2:05 PM EST - 5 months ago

ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

Jan 16, 2025, 2:25 PM EST - 5 months ago

ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Jan 15, 2025, 5:20 PM EST - 5 months ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Jan 15, 2025, 5:20 PM EST - 5 months ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Jan 6, 2025, 9:00 AM EST - 6 months ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

Dec 16, 2024, 12:24 AM EST - 6 months ago

ImmunityBio: Forging A New Plan After Recent $100 Million Offering

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

Dec 13, 2024, 2:40 PM EST - 7 months ago

ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Dec 12, 2024, 8:00 AM EST - 7 months ago

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Dec 11, 2024, 7:30 AM EST - 7 months ago

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Dec 10, 2024, 4:24 PM EST - 7 months ago

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

Nov 21, 2024, 10:00 AM EST - 7 months ago

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

Nov 19, 2024, 9:00 AM EST - 7 months ago

ImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Nov 19, 2024, 8:00 AM EST - 7 months ago

ImmunityBio Completes ANKTIVA's Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

ImmunityBio Reports Third-Quarter 2024 Financial Results

Nov 12, 2024, 7:15 AM EST - 8 months ago

ImmunityBio Reports Third-Quarter 2024 Financial Results

ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025

Oct 28, 2024, 7:53 AM EDT - 8 months ago

ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

Oct 25, 2024, 8:22 AM EDT - 8 months ago

Top 2 Health Care Stocks That May Fall Off A Cliff This Month

SRRK

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

Oct 24, 2024, 9:00 AM EDT - 8 months ago

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio's CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio

Oct 23, 2024, 3:35 PM EDT - 8 months ago

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Oct 21, 2024, 9:00 AM EDT - 8 months ago

ImmunityBio to Participate in the Jefferies London Healthcare Conference

ImmunityBio: Moving The Needle

Oct 7, 2024, 11:18 AM EDT - 9 months ago

ImmunityBio: Moving The Needle

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

Sep 21, 2024, 7:02 PM EDT - 9 months ago

ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

Sep 9, 2024, 8:30 AM EDT - 10 months ago

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

Top 3 Health Care Stocks That Are Set To Fly This Quarter

Aug 16, 2024, 7:57 AM EDT - 11 months ago

Top 3 Health Care Stocks That Are Set To Fly This Quarter

HAE PGNY

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

Aug 14, 2024, 2:13 PM EDT - 11 months ago

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

Aug 12, 2024, 8:46 AM EDT - 11 months ago

ImmunityBio's ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

Diosces
Diosces Jun. 27 at 10:07 PM
$IBRX Saddest POS ever invested in... or yeah + that other shitbag 'pharma' $ALT
1 · Reply
Cancercrusader
Cancercrusader Jun. 27 at 9:37 PM
$IBRX https://brownstone.org/articles/fda-exposed-hundreds-of-drugs-approved-without-proof-they-work/ The FDA and Big Pharma ladies and gentlemen, poisoning Americans since day one.
0 · Reply
BixbyKnolls
BixbyKnolls Jun. 27 at 9:33 PM
$IBRX Wow- Some more AH BLOCKs trades going off. Now around 15.4 million shares for today. Interesting.. any mews behind this?
1 · Reply
windswept
windswept Jun. 27 at 9:19 PM
$IBRX David Din
0 · Reply
Chuckwagon23
Chuckwagon23 Jun. 27 at 8:46 PM
$IBRX first time I read this I thought it said "retarded". Me thinking, this guy is spot on. Every morning here buddy.
0 · Reply
John_morris
John_morris Jun. 27 at 8:39 PM
$IBRX What's with that BIG VOLUME going into Close ? Anybody care to share their input.
1 · Reply
VerrrrrrrryInteresting
VerrrrrrrryInteresting Jun. 27 at 8:37 PM
$IBRX Just guessing but that's what swapping spit looks like when the HFs buy-sell from each other to avoid end of month margin calls/square up their books. Totally guessing but with market at ATHs and many high beta stocks popping the past few weeks they NEEDED this one to go/stay down. NO ONE else has an 8MM share block to sell for someone to buy. JMHO but I've seen this slimy game before with HFs, especially when other holdings are going against them. However, I HOPE it was a new buyer taking a stake for the beginning :)
0 · Reply
elitechrisvp
elitechrisvp Jun. 27 at 8:24 PM
$IBRX 😁👍
0 · Reply
Catredeye
Catredeye Jun. 27 at 8:21 PM
$IBRX My little 548 buy went through at 123-127 pm blocks of 100 and 148 for 2.74 then of course it dropped after that. Like always. No matter still waiting with my measly 9555 shares .
1 · Reply
CagedMoney
CagedMoney Jun. 27 at 8:17 PM
$IBRX Monday will be interesting
2 · Reply
BixbyKnolls
BixbyKnolls Jun. 27 at 8:16 PM
$IBRX -Does this mean he supports BioShield therapy? 🤷‍♂️https://x.com/rfkjr_official/status/1938646643496423439?s=46
1 · Reply
Smatty
Smatty Jun. 27 at 8:15 PM
$IBRX Just me or did someone buy almost 10M shares right at close?
2 · Reply
windswept
windswept Jun. 27 at 8:13 PM
$IBRX two spikes
0 · Reply
Dmck9
Dmck9 Jun. 27 at 8:11 PM
$IBRX someone loaded up big just before close!!
1 · Reply
RKwine
RKwine Jun. 27 at 8:10 PM
$IBRX who bought those shares?
1 · Reply
BixbyKnolls
BixbyKnolls Jun. 27 at 8:08 PM
$IBRX Big volume close. What was that all about?
1 · Reply
MeTN3B
MeTN3B Jun. 27 at 8:04 PM
$IBRX E*trade reflects 12m shares traded. Volume was under 5m going into close. Anyone else see this or e trade gremlin?
3 · Reply
Marusch
Marusch Jun. 27 at 7:52 PM
$IBRX Why have Vuzix and Ibrx been running in lockstep for weeks?
2 · Reply
SeniorVip
SeniorVip Jun. 27 at 7:51 PM
$IBRX Longs should be buying near the close to push the closing price higher.
1 · Reply
SevenArrows
SevenArrows Jun. 27 at 7:47 PM
$IBRX
0 · Reply
BixbyKnolls
BixbyKnolls Jun. 27 at 7:33 PM
$IBRX Real Life BioShield at work! https://www.tiktok.com/t/ZPHbJtsPDvpPJ-7LLX4/
0 · Reply
CashMoneyBoy
CashMoneyBoy Jun. 27 at 7:28 PM
$IBRX This stock is more exciting than a Diddy party !
1 · Reply